Date published: 2025-10-15

1-800-457-3801

SCBT Portrait Logo
Seach Input

KU 60019 (CAS 925701-46-8)

5.0(1)
Write a reviewAsk a question

See product citations (1)

Alternate Names:
(2R,6S-rel)-2,6-Dimethyl-N-[5-[6-(4-morpholinyl)-4-oxo-4H-pyran-2-yl]-9H-thioxanthen-2-yl-4-morpholineacetamide
Application:
KU 60019 is an ATM kinase inhibitor
CAS Number:
925701-46-8
Purity:
≥98%
Molecular Weight:
547.67
Molecular Formula:
C30H33N3O5S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Available in US only.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

KU 60019 is a potent inhibitor of ATM kinase. Against a panel of 229 protein kinases, it exhibits little to no nonspecific target effects, displaying similar target selectivity to KU 55933. KU 60019 has also been shown to inhibit invasion and migration of human glioma cells in vitro. ATM helps regulate the cell cycle, especially in response to DNA damage. Inhibiting ATM can disrupt the normal cell cycle checkpoints, allowing cells with DNA damage to progress through the cell cycle, which can lead to mutations. ATM also plays a key role in the cellular response to ionizing radiation, which induces DNA double-strand breaks. Cells with inhibited ATM are often more sensitive to radiation.


KU 60019 (CAS 925701-46-8) References

  1. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control.  |  Golding, SE., et al. 2012. Cell Cycle. 11: 1167-73. PMID: 22370485
  2. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.  |  Biddlestone-Thorpe, L., et al. 2013. Clin Cancer Res. 19: 3189-200. PMID: 23620409
  3. Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019.  |  Vecchio, D., et al. 2014. Int J Cancer. 135: 479-91. PMID: 24443327
  4. Chemical screening identifies ATM as a target for alleviating senescence.  |  Kang, HT., et al. 2017. Nat Chem Biol. 13: 616-623. PMID: 28346404
  5. ATM in DNA repair in cancer.  |  Jin, MH. and Oh, DY. 2019. Pharmacol Ther. 203: 107391. PMID: 31299316
  6. Screening of kinase inhibitors downregulating PD-L1 expression via on/in cell quantitative immunoblots.  |  Xie, Y., et al. 2020. Eur J Pharm Sci. 142: 105088. PMID: 31626963
  7. Small molecule inhibition of ATM kinase increases CRISPR-Cas9 1-bp insertion frequency.  |  Bermudez-Cabrera, HC., et al. 2021. Nat Commun. 12: 5111. PMID: 34433825
  8. PTEN mutant non-small cell lung cancer require ATM to suppress pro-apoptotic signalling and evade radiotherapy.  |  Fischer, T., et al. 2022. Cell Biosci. 12: 50. PMID: 35477555
  9. Inhibition of PLK3 Attenuates Tubular Epithelial Cell Apoptosis after Renal Ischemia-Reperfusion Injury by Blocking the ATM/P53-Mediated DNA Damage Response.  |  Deng, W., et al. 2022. Oxid Med Cell Longev. 2022: 4201287. PMID: 35783188
  10. Co-inhibition of ATM and ROCK synergistically improves cell proliferation in replicative senescence by activating FOXM1 and E2F1.  |  Yang, EJ., et al. 2022. Commun Biol. 5: 702. PMID: 35835838
  11. Ataxia Telangiectasia-Mutated Is Activated but Not Required for Productive Autographa californica Multiple Nucleopolyhedrovirus Infection.  |  Erickson, JR., et al. 2022. J Virol. 96: e0126922. PMID: 36314821
  12. Effects of different drugs and hormone treatment on Toxoplasma gondii glutathione S-transferase 2.  |  Li, S., et al. 2022. Parasit Vectors. 15: 461. PMID: 36510329
  13. Ataxia-Telangiectasia Mutated Is Involved in Autolysosome Formation.  |  Hwang, M., et al. 2023. Biomol Ther (Seoul).. PMID: 36941082

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

KU 60019, 10 mg

sc-363284
10 mg
$243.00
US: Only available in the US

KU 60019, 50 mg

sc-363284A
50 mg
$1015.00
US: Only available in the US